---
title: "688578.SH (688578.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688578.SH/news.md"
symbol: "688578.SH"
name: "688578.SH"
parent: "https://longbridge.com/en/quote/688578.SH.md"
datetime: "2026-05-21T08:49:48.191Z"
locales:
  - [en](https://longbridge.com/en/quote/688578.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688578.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688578.SH/news.md)
---

# 688578.SH (688578.SH) — Related News

### [Directly hitting the Allist shareholder meeting: Major products support the market, more growth anxieties need to be resolved under the patent cliff](https://longbridge.com/en/news/286646835.md)
*2026-05-16T13:42:18.000Z*
> Allist's shareholders meeting discussed the company's future development, particularly how to respond to the challenges 

### [Another weight loss clinical trial plans to recruit 1,980 participants, a target that has been forgotten for nearly 20 years makes a comeback; Allist's flagship product conducts a comparative study with mainstream targeted drugs for lung cancer | Exploring Innovative Drugs](https://longbridge.com/en/news/286104228.md)
*2026-05-12T12:48:14.000Z*
> This week, the pharmaceutical and biotechnology index fell by 0.65%, while innovative drugs (BK1106) rose by 0.62%. The 

### [The commercialization of domestic innovative drugs is accelerating, and the Ping An Medical Innovation ETF and the Ping An CSI HK Equities Medical and Health Integration ETF are receiving significant attention](https://longbridge.com/en/news/285307086.md)
*2026-05-06T03:24:14.000Z*
> The commercialization of domestic innovative drugs is accelerating, and the Ping An CSI Medicine and Medical Device Inno

### [A-share 2025 Sales Gross Margin Ranking: Pharmaceutical Biology and Computer Industries Dominate](https://longbridge.com/en/news/284984638.md)
*2026-05-03T05:36:49.000Z*
> The 2025 annual report of A-shares shows that the sales gross margin of the beauty care and food and beverage industries

### [Allist: The company's products have been included in the proposed list of breakthrough therapies](https://longbridge.com/en/news/284535155.md)
*2026-04-29T09:33:00.000Z*
> Allist announced that the company's product, citric acid gorairesu tablets combined with AST24082 capsules, is used for 

### [Allist: The clinical study for the new indication of Fumetinib has been approved](https://longbridge.com/en/news/284535148.md)
*2026-04-29T09:33:00.000Z*
> Allist announced that it recently received the "Drug Clinical Trial Approval Notification" approved and issued by the Na

### [Fumetin will "sell explosively" in 2025, but Allist is in a state of anxiety](https://longbridge.com/en/news/283995976.md)
*2026-04-24T11:46:57.000Z*
> Allist released its annual report for 2025, expecting total operating revenue of 5.187 billion yuan, a year-on-year incr

### [Allist released its first-quarter results, with a net profit attributable to the parent company of 636 million yuan, a year-on-year increase of 54.94%](https://longbridge.com/en/news/283683635.md)
*2026-04-22T14:16:12.000Z*
> Allist released its Q1 2026 performance, with revenue of 1.584 billion yuan, a year-on-year increase of 44.19%; net prof

### [Allist 2025 Financial Report Insight: Single Product Supports Revenue of 5.2 Billion, Subsequent Growth Lacks Momentum](https://longbridge.com/en/news/283674372.md)
*2026-04-22T13:17:22.000Z*
> Allist announced its 2025 financial report, with revenue of 5.187 billion yuan, a year-on-year increase of 45.80%; net p